Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16726
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHertzberg, Mark-
dc.contributor.authorGandhi, Maher K-
dc.contributor.authorTrotman, Judith-
dc.contributor.authorButcher, Belinda-
dc.contributor.authorTaper, John-
dc.contributor.authorJohnston, Amanda-
dc.contributor.authorGill, Devinder-
dc.contributor.authorHo, Shir-Jing-
dc.contributor.authorCull, Gavin-
dc.contributor.authorFay, Keith-
dc.contributor.authorChong, Geoffrey-
dc.contributor.authorGrigg, Andrew P-
dc.contributor.authorLewis, Ian D.-
dc.contributor.authorMilliken, Sam-
dc.contributor.authorRenwick, William-
dc.contributor.authorHahn, Uwe-
dc.contributor.authorFilshie, Robin-
dc.contributor.authorKannourakis, George-
dc.contributor.authorWatson, Anne-Marie-
dc.contributor.authorWarburton, Pauline-
dc.contributor.authorWirth, Andrew-
dc.contributor.authorSeymour, John F-
dc.contributor.authorHofman, Michael S-
dc.contributor.authorHicks, Rodney J-
dc.contributor.authorAustralasian Leukaemia and Lymphoma Group (ALLG) -
dc.date2016-11-10-
dc.date.accessioned2017-07-26T00:50:44Z-
dc.date.available2017-07-26T00:50:44Z-
dc.date.issued2017-02-
dc.identifier.citationHaematologica 2017; 102(2): 356-363en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16726-
dc.description.abstractIn the treatment of diffuse large B-cell lymphoma, a persistently positive [18F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a poor prognosis. In this prospective multi-center phase II study, we sought to establish whether treatment intensification with R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) chemotherapy followed by 90Y-ibritumomab tiuxetan-BEAM (BCNU, etoposide, cytarabine, and melphalan) for high-risk diffuse large B-cell lymphoma patients who are positive on interim PET scan after 4 cycles of R-CHOP-14 (rituximab, cyclophosphamide, doxorubicin, and prednisone) can improve 2-year progression-free survival from a historically unfavorable rate of 40% to a rate of 65%. Patients received 4 cycles of R-CHOP-14, followed by a centrally-reviewed PET performed at day 17-20 of cycle 4 and assessed according to International Harmonisation Project criteria. Median age of the 151 evaluable patients was 57 years, with 79% stages 3-4, 54% bulk, and 54% International Prognostic Index 3-5. Among the 143 patients undergoing interim PET, 101 (71%) were PET-negative (96 of whom completed R-CHOP), 42 (29%) were PET-positive (32 of whom completed R-ICE and 90Y-ibritumomab tiuxetan-BEAM). At a median follow up of 35 months, the 2-year progression-free survival for PET-positive patients was 67%, a rate similar to that for PET-negative patients treated with R-CHOP-14 (74%, P=0.11); overall survival was 78% and 88% (P=0.11), respectively. In an exploratory analysis, progression-free and overall survival were markedly superior for PET-positive Deauville score 4 versus score 5 (P=0.0002 and P=0.001, respectively). Therefore, diffuse large B-cell lymphoma patients who are PET-positive after 4 cycles of R-CHOP-14 and who switched to R-ICE and 90Y-ibritumomab tiuxetan-BEAM achieved favorable survival outcomes similar to those for PET-negative R-CHOP-14-treated patients. Further studies are warranted to confirm these promising results. (Registered at: ACTRN12609001077257).en_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectLymphoma, Large B-Cell, Diffuseen_US
dc.subjectPositron-Emission Tomographyen_US
dc.titleEarly treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleHaematologicaen_US
dc.identifier.affiliationDepartment of Haematology, Prince of Wales Hospital and University of NSW, Randwick, NSW, Australiaen_US
dc.identifier.affiliationThe University of Queensland Diamantina Institute Woolloongabba, Brisbane, QLD, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, Repatriation General Hospital Concord and University of Sydney, NSW, Australiaen_US
dc.identifier.affiliationWriteSource Medical Pty Ltd., Lane Cove, NSW, Australiaen_US
dc.identifier.affiliationNepean Cancer Care Centre, Nepean Hospital, Nepean, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, Westmead Hospital, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, St George Hospital, Kogarah, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, Royal North Shore Hospital, St Leonard's, NSW, Australiaen_US
dc.identifier.affiliationOlivia Newton John Cancer & Wellness Centre, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, St Vincent's Hospital Darlinghurst, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, The Queen Elizabeth Hospital, SA, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationBallarat Oncology and Haematology Service and Fiona Elsey Cancer Research Institute, Ballarat, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, Liverpool Hospital, Liverpool, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, Wollongong Hospital, Wollongong, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, Peter MacCallum Cancer Centre East Melbourne and University of Melbourne, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Cancer Imaging, Peter MacCallum Cancer Centre East Melbourne, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28143954en_US
dc.identifier.doi10.3324/haematol.2016.154039en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherChong, Geoffrey
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.